semaglutide glp 1 analogue The Landscape Of GLP-1 Receptor Agonists In Diabetes And Obesity Treatment Comparing Ozempic, Wegovy and Other

Description

For people aged 18-29, only 1% had ever used GLP-1 drugs to treat chronic conditions, while 7% of those in this age group had used them for weight loss, and a further 3% had used them for chronic conditions and weight loss

The only indication that there may be risks associated with taking the companies products came in the last line of a long written disclaimer at the end of the ad: See website for details and important safety information. (A similar disclaimer appears at the end of the Hims ad focusing on its ED medication.) Since the controversy over the Super Bowl ad, Hims and Hers have included a disclaimer in some of their ads regarding how their compounded weight-loss products have not been approved by the FDA and require an online consultation with a licensed provided who will determine if a prescription is appropriate. But the disclaimer doesnt appear everywhere and it still refers consumers to a company website for important safety information. As for the other telehealth companies mentioned earlier, Willow does not disclose any side effects associated with its compounded GLP-1 products in the social media post shown above and requires that consumers scroll more than halfway down product pages to learn about potential health risks

[DOI] [PMC free article] [PubMed] [Google Scholar] 79.Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, et al

Certain situations may require individualized evaluation, but treatment outside approved indications is determined by healthcare providers based on medical judgment and patient-specific circumstances